@article{5cde80c1b8d34bafb3556afc7738e91e,
title = "Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma",
abstract = "Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.",
author = "Merryman, {Reid W.} and Carreau, {Nicole A.} and Advani, {Ranjana H.} and Spinner, {Michael A.} and Herrera, {Alex F.} and Robert Chen and Sarah Tomassetti and Radhakrishnan Ramchandren and Muhammad Hamid and Sarit Assouline and Raoul Santiago and Nina Wagner-Johnston and Suman Paul and Jakub Svoboda and Bair, {Steven M.} and Barta, {Stefan K.} and Yang Liu and Sunita Nathan and Reem Karmali and Madelyn Burkart and Pallawi Torka and David, {Kevin A.} and Catherine Wei and Frederick Lansigan and Lukas Emery and Daniel Persky and Smith, {Sonali M.} and James Godfrey and Julio Chavez and Cohen, {Jonathan B.} and Troxel, {Andrea B.} and Catherine Diefenbach and Philippe Armand",
note = "Funding Information: R.W.M. gratefully acknowledges support from an ASH Research Training Award for Fellows, the ASH Clinical Research Training Institute, an ASBMT New Investigator Award, and the LRF Lymphoma Clinical Research Mentoring Program. P.A. gratefully acknowledges the support of the Harold and Virginia Lash Foundation, as well as the Leukemia and Lymphoma Society. Publisher Copyright: {\textcopyright} AlphaMed Press 2020",
year = "2020",
month = jun,
day = "1",
doi = "10.1634/theoncologist.2020-0040",
language = "English (US)",
volume = "25",
pages = "e993--e997",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",
}